BIOTECH SQUIRE
PARTNERING PIPELINE INFRASTRUCTURE • US & EU BIOTECH

Structured Partnering Pipeline Control for Early-Stage Biotech CEOs.

Biotech Squire designs and deploys dedicated pharma partnering systems for asset-centric biotech leadership teams—replacing fragmented email threads and manual spreadsheets with clear, auditable operational visibility.

US & EU Asset-Centric Biopharma Pre-IND Through Early Clinical Stage Partnering Pipelines, Not Regulatory Consulting
Operational Context

Long Partnering Cycles Outgrow Founder Inboxes.

Biopharma licensing and co-development discussions routinely span 9 to 12 months or longer. They begin at major partnering conferences—BIO International Convention, BIO-Europe, and J.P. Morgan Healthcare Week—and continue through online partnering portals such as partneringONE and BIO One-on-One Partnering. Over that horizon, critical context scatters across executive inboxes, ad-hoc slide decks, and versioned spreadsheets.

Structured pipeline infrastructure preserves every external signal cleanly—supporting leadership whether reporting to institutional directors or preparing for upcoming venture financing.

Board-Backed CEOs

Consistent Visibility for an Active Board of Directors

Give directors clear, recurring visibility into active pharma diligence stages, counterparty momentum, and pending follow-ups ahead of every board meeting without manual pre-meeting reconciliation.

Pre-Board & Grant-Funded CEOs

Auditable Track Record Ahead of Series A Diligence

Translational teams advancing through NIH SBIR/STTR or Horizon Europe / EIC Accelerator milestones build a structured, inspectable record of pharma interest before Series A investors audit the pipeline.

Core Infrastructure Pillars

Purpose-Built Governance Around Biopharma Partnering Mechanics.

01 Biopharma Stages

Unified Pharma Pipeline Architecture

Replace generic sales pipelines with purpose-built biopharma stages—Non-Confidential Outreach, CDA Executed, Data Room & Scientific Diligence, and Term Sheet / Negotiation—giving leadership an exact view of every active asset conversation.

Non-Confidential Outreach CDA Executed Data Room & Scientific Diligence Term Sheet / Negotiation
02 Court Accountability

Deterministic Next-Action Ownership

Eliminate ambiguous status updates with binary next-action ownership—Active — Ball in Our Court vs. Active — Ball in Pharma's Court—paired with inactivity visibility so high-priority pharma threads never quietly stall.

Active — Ball in Our Court Active — Ball in Pharma's Court
03 Trigger Retention

Conditional Pass & Future-Data Capture

Maintain a strict distinction between a definitive Hard Pass and a Conditional Pass — Future Data Trigger, preserving pharma feedback tied to upcoming preclinical, GLP tox, or early clinical readouts.

Conditional Pass — Future Data Trigger Hard Pass
04 Audit Visibility

Board & Diligence-Ready Reporting

Generate structured, human-verified partnering summaries designed for recurring Board of Directors updates and institutional Series A diligence without manual weekend spreadsheet assembly.

Board of Directors Packets Series A Data Rooms
Introductory Conversation

Bring Institutional Structure to Your Partnering Pipeline.

Schedule a concise 15-minute conversation to review your current partnering visibility and discuss upcoming board or Series A milestones.